July 28, 2016
Onxeo Reports First-Half 2016 Business Update and Consolidated Financials
Media
July 28, 2016
Cash position and revenue for the 1st semester of 2016
July 27, 2016
Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America
July 21, 2016
Nexstim Plc announces long-term financing arrangements in the form of a joint deal with Bracknor and Sitra
July 13, 2016
GenSight Biologics announces successful IPO on Euronext Paris
July 12, 2016
Interim report H1 2016: Positive cash flow and EBIT. Expansion of Zubsolv® to new markets and improved market access position in the US.
July 08, 2016
Publication of prospectus, listing on Oslo Axess and subsequent offering
July 07, 2016
Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016
July 07, 2016
Orexo welcomes increased access to treatment for patients with opioid dependence in the US
July 07, 2016
Completion of private placement, registration of share capital increase
